Clinical trials in Ahlen

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates. Safety profiling of a trastuzumab‑deruxtecan based regimen Efficacy comparison using 3‑year distant disease‑free survival Assessment of sacituzumab govitecan with or without pembrolizumab Evaluation of pathological complete response as a co‑primary endpoint The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical trials in Ahlen

2 trials in Ahlen

Triple negative breast cancer+4

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Breast cancer+2

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Filter the trials

Other cities in Germany

Clinical research in Ahlen

Prefer not to search? Our Concierge searches the trials for you.

Clinical trials in Ahlen

2 trials in Ahlen

Triple negative breast cancer+4

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Breast cancer+2

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Other cities in Germany

Related

Clinical research in Ahlen

Prefer not to search? Our Concierge searches the trials for you.